Gastrointestinal intolerance, particularly nausea and vomiting, may affect adherence despite their tendency to diminish over time ( Looking ahead, the future of GLP-1based therapy will depend on addressing safety concerns, improving long-term adherence, and expanding clinical indications
Shipping & Freshness
Incretin-Based Glucose-Lowering Medications and the Risk of Acute Pancreatitis and Malignancies: A Meta-Analysis Based on Cardiovascular Outcomes Trials
My body needed the GLP-1 and clinical support, the tennis legend says in a statement
Without RCT data on semaglutide for the management of BAD, it is difficult to evaluate its safety and efficacy compared with other BAD therapeutics, but the abovementioned case underscores that newer, longer-acting, and more potent GLP-1RAs not necessarily provide better treatment results in BAD as compared with older, shorter-acting, and less potent GLP-1RAs such as liraglutide
Some patients may experience gastrointestinal complications like gastroparesis or reflux, and rare risks include pancreatitis or low blood pressure
